US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Aditxt, Inc.

< Previous 1 2 3 4 Next >
News headline image
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
News headline image
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
News headline image
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
News headline image
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
News headline image
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
News headline image
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
News headline image
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
News headline image
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
News headline image
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF EVFM OTC TSX:APLI
News headline image
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
News headline image
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
News headline image
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
From Aditxt, Inc.
Via Business Wire
Tickers ADTX APLIF OTC TSX:APLI
News headline image
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
From Aditxt, Inc.
Via Business Wire
Tickers ADTX EVFM
< Previous 1 2 3 4 Next >